TuHURA Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HURA research report →
About the company
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments.
- CEO
- James A. Bianco
- IPO
- 2013
- Employees
- 19
- HQ
- Tampa, US
Price Chart
- Market Cap
- $155.39M
- P/E
- -3.98
- P/S
- 0.00
- P/B
- 6.31
- EV/EBITDA
- -4.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -153.99%
- ROIC
- -135.50%
- Revenue
- $0 · 0.00%
- Net Income
- $-30,060,333 · -38.64%
- EPS
- $-0.63 · 48.09%
- Op Income
- $-31,795,939
- FCF YoY
- -87.37%
- 52W High
- $3.90
- 52W Low
- $0.41
- 50D MA
- $2.33
- 200D MA
- $1.87
- Beta
- -0.04
- Avg Volume
- 903.10K
Get TickerSpark's AI analysis on HURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 28, 26 | Bianco James A. | other | 150,000 |
| Feb 12, 26 | Tendler Craig | other | 156,240 |
| Feb 12, 26 | Ng George K | other | 156,240 |
| Feb 12, 26 | MANUSO JAMES S J | other | 156,240 |
| Feb 12, 26 | List Alan | other | 156,240 |
| Feb 12, 26 | Hoffman Robert E. | other | 156,240 |
| Jan 6, 26 | Dearborn Dan | other | 273,696 |
| Jan 6, 26 | Bianco James A. | other | 610,332 |
| Dec 12, 25 | Dearborn Dan | other | 1,531,367 |
| Dec 12, 25 | Bianco James A. | other | 3,414,891 |
Our HURA coverage
Recent articles, reports, and earnings notes.
No research on HURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HURA report →Similar companies
Peers in the same neighborhood.